Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Conference on Cancer Diagnostics Dubai, UAE.

Day 1 :

OMICS International Oncodiagnostics-2017 International Conference Keynote Speaker Mohamed El-Far photo
Biography:

Mohamed El-Far has worked in biochemistry for 40 years, published over 90 peer-reviewed papers. He is serving on the editorial boards and Hon. Editor to four international journals. He acts as UNESCO expert in science and technology. He served as visiting professor to University of California, Utah laser center and Mayo clinic for several years, also to Cardiff and Swansea Universities, UK. He is a member of International Photodynamic Association and Royal Society of Chemistry, UK

Abstract:

We will present our long-term team(s) experience of photodynamic therapy (PDT) of certain types of tumors. This presentation aims to show how to enhance efficacy of PDT and ways to increase it, the lecture includes our search for ideal photosensitizers as we were the first to show that natural uroporphyrin may be used for the diagnosis and treatment of tumors by using PDT. We will present data to show bio-distribution and selective tumor localization of endogenous porphyrins induced and stimulated by 5-Aminolevulinic acid as a newly developed technique Moreover, mechanism of action of PDT will be discussed, as well as our novel approaches to enhance efficacy of PDT and innovations to increase it including modification and synthesis of newly developed photosensitizers. We will present our vast experience of experimental as well as clinical applications of PDT of tumors and discuss our results obtained during four decades.

 

Keynote Forum

Diana Anderson

University of Bradford, UK

Keynote: An Empirical Assay for Assessing Genomic Sensitivity and for Improving Cancer Diagnostics

Time : 09:40- 10:20

OMICS International Oncodiagnostics-2017 International Conference Keynote Speaker Diana Anderson photo
Biography:

Professor Anderson holds the Established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. She has 450+ peer-reviewed papers, 8 books, has successfully supervised 26 PhDs, and been a member of editorial boards of 10 international journals. She has been or is Editor in Chief of a book Series on toxicology for J.Wiley and sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organisations, such as the WHO, NATO, TWAS, UNIDO and the OECD

Abstract:

             Detection tests have been developed for many cancers, but there is no single test to identify cancer in general. We have developed such an assay. In this modified patented Comet assay, we investigated peripheral lymphocytes of 208 individuals: 20 melanoma, 34 colon cancer, 4 lung cancer patients 18 suspect melanoma, 28 polyposis, 10 COPD patients and 94 healthy volunteers. The natural logarithm of the Olive tail moment was plotted for exposure to UVA through different agar depths for each of the above groups and analysed using a repeated measures regression model. Response patterns for cancer patients formed a plateau after treating with UVA where intensity varied with different agar depths. In comparison, response patterns for healthy individuals returned towards control values and for pre/suspected cancers, were intermediate with less of a plateau. All cancers tested exhibited comparable responses. Analyses of Receiver Operating Characteristic curves, of mean log Olive tail moments, for all cancers plus pre/suspected-cancer versus controls gave a value for the area under the curve of 0.87; for cancer versus pre/suspected-cancer plus controls the value was 0.89; and for cancer alone versus controls alone (excluding pre/suspected-cancer), the value was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable complementary measures. Evidence presented indicates that this modified assay shows promise as both a stand-alone test and as a possible adjunct to other investigative procedures, as part of detection programmes for a range of cancers.

Keynote Forum

Suheil Simaan

Lebanese American University, Lebanon

Keynote: Statistical analysis of consecutive one thousand breast cancer cases operated personally by the author in Syria

Time : 10:20- 11:00

OMICS International Oncodiagnostics-2017 International Conference Keynote Speaker Suheil Simaan photo
Biography:

Suheil Fayek Simaan has obtained his MD from the American University of Beirut and General Surgical training at the Cleveland Metro Gen Hospital and the Mayo Clinic. He has also received his Cancer Surgery training at the Memorial Sloan Kettering Cancer Center NYC. He has served as an Editor in Chief of the journal Advances of Medical Science.

Abstract:

The behavior and characteristics of breast cancer (BC) in Syria was studied through reviewing the charts of 665 breastcancer patients I personally operated within the last five years. According to our MOH Cancer Registry, based on 8000 breast cancer cases collected from several hospitals in Syria; BC accounted for 30% of female cancers in Syria. According to my personal studied cases (665), the average age of incidence was 48 years which is consistent with that figure in neighboring countries like Lebanon, Jordan and Egypt. Those patients below the age of 40 accounted for 20% of cases. This might be explained by the fact that according to our population pyramid, 82% of our people are under the age of 40. Lesions below 2 cm in size were 21%, 2-5 cm in size accounted for 55%. Negative axillary LN's were 47%. Positive ER/PR was 56%. Positive HER2
accounted for 32%. Modified Radical Mastectomy (MRM) was done on 72%. Conservative Surgery (CS) accounted for only 20%. Conversion from CS to MRM accounted for 8%. Local recurrence after CS was 13%. Locally advanced BC was 12%. Our periodic campaigns in breast cancer awareness are paying off in early detection and better survival.